Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity
-
Park Jin-young Denies Cult Allegations Against Firstfruits Group
-
Writer Realizes She Is Lesbian After Child Comes Out as Transgender
-
MotorTrend's Top Electric Vehicle Picks for 2026
-
GTA 6 Advertising Strategy and Disc Version Controversy
-
St Francis School Leads €60,000 EU Project to Transform Early Childhood Education
-
IT’S TIME TO SHINE: ELEKTROS Thanks Its Shareholders and Looks Toward a Brighter Future in Critical Minerals and EV Technology
-
ELEKTROS Invites Shareholders to Shine Bright as the Holiday Season Nears, with Focus on Lithium, Critical Minerals and EV Innovation
-
As the Most Wonderful Time of the Year Approaches, ELEKTROS Celebrates Its Shareholders and Looks Ahead to a Bright Future
-
How to Find Joy in a Simpler, More Intentional Lifestyle
-
1986 Yugo GT with 121 Miles Listed for Sale on Bring a Trailer
-
Ukrainian MP Oleksiy Kucherenko Accidentally Exposes Himself During Live TV Interview
-
Malta Stuns Sweden with Late Penalty Comeback in Rugby Europe Trophy
Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") announced today that warrant exchanges and exercises over the last four trading days have generated $3.1 million in cash. The proceeds will fund working-capital needs and advance the Company's peptide-based drug candidates for stress-related and central-nervous-system disorders.
This financing comes as Protagenic executes on its previously announced business combination with Phytanix Bio Inc. (May 19, 2025). The combination has brought together six complementary drug programs spanning stress disorders, epilepsy, obesity, and other indications under one company.
About Protagenic Therapeutics, Inc.
Protagenic Therapeutics (Nasdaq: PTIX) is pioneering peptides for stress-related disorders. For more information, visit www.protagenic.com.
About Phytanix Bio Inc.
Phytanix Bio is an innovative pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and "cannabinoid-like" molecules. For more information, visit www.phytanix.com.
Forward-Looking Statements:
This press release contains forward-looking statements concerning Protagenic Therapeutics' product candidates and clinical trial plans. These statements are subject to various risks and uncertainties. Investors are urged to exercise caution and not place undue reliance on these forward-looking statements.
Company Contact:
Alexander K. Arrow, MD, CFA
Chief Financial Officer
Protagenic Therapeutics, Inc.
149 Fifth Ave, Suite 500, New York, NY 10010
Tel: 213-260-4342
Email: [email protected]
SOURCE: Protagenic Therapeutics, Inc.
View the original press release on ACCESS Newswire
G.P.Martin--AT
